Sintilimab and bevacizumab after surgery for ruptured liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining two immune-based drugs (sintilimab and a bevacizumab biosimilar) after surgery can prevent liver cancer from returning in people whose tumor had ruptured. It’s for patients who have had a complete surgical removal of a ruptured hepatocellular carcinoma and are now cancer-free on imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a ruptured liver tumor that was completely removed during surgery.
- You are between 18 and 75 years old.
- Your cancer is stage I or II (CNLC system) and has not spread outside the liver.
- You have good liver function (Child-Pugh A) and can care for yourself (ECOG 0-1).
- You do not have active autoimmune disease, serious infections, or uncontrolled heart or bleeding conditions.
- If you have hepatitis B, it must be well controlled with antiviral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (sintilimab and lenvatinib) after surgery to remove liver cancer that has a specific blood vessel pattern (VETC). The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of two drugs (bevacizumab and adebrelimab) plus a special procedure called TACE-HAIC to treat advanced liver cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective as a first-line treatment.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
This trial tests whether adding a combination of three drugs (anti-CTLA-4, anti-PD-1, and bevacizumab) before and after surgery can help people with resectable liver cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests whether the immunotherapy drug Sintilimab, given after surgery, can help prevent liver cancer from coming back in people whose tumors had tiny blood vessel invasion. It is for patients who have fully recovered from surgery and have not had other cancer treatments before.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.